Scarica l'app Stockscreener
117.62
0.15%
0.18
Dopo l'orario di chiusura:
117.46
-0.16
-0.14%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$117.44
Aprire:
$117.46
Volume 24 ore:
1.03M
Relative Volume:
1.06
Capitalizzazione di mercato:
$11.84B
Reddito:
$2.24B
Utile/perdita netta:
$385.90M
Rapporto P/E:
63.24
EPS:
1.86
Flusso di cassa netto:
$440.10M
1 W Prestazione:
-7.51%
1M Prestazione:
-0.33%
6M Prestazione:
-17.34%
1 anno Prestazione:
+7.97%
Intervallo 1D:
$116.33
$118.31
Intervallo di 1 settimana:
$116.33
$128.24
Portata 52W:
$108.14
$157.98
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Nome
Neurocrine Biosciences Inc
Settore
Telefono
(858) 617-7600
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Confronta NBIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| NBIX | 117.62 | 11.84B | 2.24B | 385.90M | 440.10M | 1.86 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Ripresa | Citigroup | Neutral |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Reiterato | Mizuho | Neutral |
| 2023-07-24 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-09-26 | Iniziato | Wells Fargo | Equal Weight |
| 2022-06-06 | Ripresa | Jefferies | Buy |
| 2022-03-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Underperform |
| 2021-11-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-08-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-05-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Iniziato | Raymond James | Outperform |
| 2020-09-30 | Iniziato | The Benchmark Company | Hold |
| 2020-08-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Downgrade | Goldman | Buy → Neutral |
| 2020-06-09 | Iniziato | Wedbush | Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-24 | Iniziato | William Blair | Outperform |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-05 | Iniziato | Guggenheim | Neutral |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-02-06 | Reiterato | BofA/Merrill | Buy |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-11-21 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Empowered Funds LLC Grows Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Sumitomo Mitsui Trust Group Inc. Sells 11,502 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Impax Asset Management Group plc Raises Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
GSA Capital Partners LLP Increases Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Position Boosted by Plato Investment Management Ltd - MarketBeat
Aigen Investment Management LP Purchases Shares of 5,948 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
(NBIX) Trading Report - Stock Traders Daily
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus - Yahoo Finance
Strategic Sale: EIRY ROBERTS Decides To Exercise Options Worth $334K At Neurocrine Biosciences - Benzinga
Principal Financial Group Inc. Sells 120,576 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio - Benzinga
Neurocrine Biosciences: Healthcare Marketing Impact Awards 2024 - Modern Healthcare
Why AbbVie’s disappointing schizophrenia drug trial bodes well for Bristol Myers - MarketWatch
How Neurocrine Biosciences helps health care professionals diagnose a movement disorder - Ad Age
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned - BioPharma Dive
Neurocrine Biosciences (NASDAQ:NBIX) Earns "Hold" Rating from Needham & Company LLC - MarketBeat
Los Angeles Capital Management LLC Increases Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Fiera Capital Corp Decreases Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels (NASDAQ:NBIX) - Seeking Alpha
Summit Global Investments Sells 24,024 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences' (NASDAQ:NBIX) Strong Earnings Are Of Good Quality - Yahoo Finance Australia
Beacon Harbor Wealth Advisors Inc. Buys Shares of 47,917 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Kornitzer Capital Management Inc. KS Makes New $3.59 Million Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences presents new KINECT®-HD data showing consistent efficacy across 19 subgroups and improvements in aspects of emotional health with Ingrezza (valbenazine) capsules - PharmaLive
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules - PR Newswire
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Van ECK Associates Corp - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Nisa Investment Advisors LLC - MarketBeat
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - GlobeNewswire Inc.
Impax Asset Management Group plc Grows Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by Robeco Institutional Asset Management B.V. - MarketBeat
Neurocrine Biosciences to Participate at Investor Conferences in November - PR Newswire
Neurocrine Biosciences' SWOT analysis: navigating challenges in a competitive biotech stock landscape - Investing.com
Positive results for Neurocrine’s Ingrezza in tardive dyskinesia - The Pharma Letter
AlphaCentric Advisors LLC Raises Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine (NBIX) to Present at 3 Major Healthcare Conferences in November | NBIX Stock News - StockTitan
Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules - PR Newswire
Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia - StockTitan
Cantor Fitzgerald Has Weak Estimate for NBIX FY2024 Earnings - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Rating Lowered to "Buy" at StockNews.com - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2024 Earnings Call Transcript - MSN
abrdn plc Sells 24,723 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine shares target upgraded, market perform rating on positive outlook By Investing.com - Investing.com Australia
Neurocrine Biosciences (NASDAQ:NBIX) Earns Buy Rating from HC Wainwright - MarketBeat
Mirae Asset Global Investments Co. Ltd. Acquires 9,601 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Earnings call: Neurocrine Biosciences reports strong Q3 growth, plans ahead - Investing.com
Neurocrine: Q3 Earnings Snapshot - The Pioneer
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates - MSN
Neurocrine stock jumps 9% on strong Ingrezza sales, stock buyback - MSN
Forsta AP Fonden Sells 10,400 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight - Yahoo Finance
Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.54%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):